homocysteine-thiolactone-2-chloronicotinamide has been researched along with phenylephrine in 1 studies
Studies (homocysteine-thiolactone-2-chloronicotinamide) | Trials (homocysteine-thiolactone-2-chloronicotinamide) | Recent Studies (post-2010) (homocysteine-thiolactone-2-chloronicotinamide) | Studies (phenylephrine) | Trials (phenylephrine) | Recent Studies (post-2010) (phenylephrine) |
---|---|---|---|---|---|
9 | 0 | 6 | 13,797 | 857 | 2,083 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Janković, G; Kostić-Rajačić, S; Rizvić, E; Savić, MM | 1 |
1 other study(ies) available for homocysteine-thiolactone-2-chloronicotinamide and phenylephrine
Article | Year |
---|---|
Atypical sympathomimetic drug lerimazoline mediates contractile effects in rat aorta predominantly by 5-HT2A receptors.
Topics: Animals; Aorta, Thoracic; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Niacinamide; Phenylephrine; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1D; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Serotonin Antagonists; Sympathomimetics; Vasoconstrictor Agents | 2017 |